Thiomorpholino antisense oligonucleotides for treating PTP1B-related diseases
Patent Information
- Application Number
- JP2025527696
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-14
- Filing Date
- 2023-11-13
- Publication Date
- 2026-10-07
AI Technical Summary
Current chemical approaches for splice switching, such as phosphorodiamidate morpholino oligomers (PMOs), 2'-O-methyl (2'-OMe), and 2'-O-methoxyethyl (2'-MOE) oligomers, face limitations including toxicity, rapid excretion, difficulty in synthesis, and inability to form complexes with transfection reagents, hindering their therapeutic efficacy.
Development of thiomorpholino (TMO) antisense oligonucleotides (ASOs) that induce exon skipping in the PTPN1 gene transcript, specifically targeting exon 2, to inhibit the expression of protein tyrosine phosphatase-1B (PTP1B) protein, thereby reducing functional PTP1B production.
The TMO ASOs effectively reduce the production of functional PTP1B protein, addressing insulin resistance, leptin resistance, obesity, Rett syndrome, and cancer by altering pre-mRNA splicing to produce truncated or nonsense proteins, thus restoring normal metabolic and signaling pathways.